Oxurion NV Business Update and First Half 2020 Financial Results to be announced on 17 September

hafiz caem

TipRanks

Oppenheimer: These 2 Stocks Are Poised to Surge by Over 100%

When it comes to the market’s wild swings, is the glass half empty or half full? Oppenheimer’s chief investment strategist John Stoltzfus is taking the latter view.Despite the volatility that has ruled the market over the last few weeks, Stoltzfus actually likes what he’s witnessing in both the market and the economy. In particular, he points to U.S. companies that have been outperforming most other markets around the world as exciting plays, with the innovation in the U.S. reflecting a key component of his bullish thesis.“The U.S. is outperforming most of the markets around the world — whether it’s developed markets or emerging markets… We’ve taken out the froth that had come into the market in certain [mega cap] names. It may be a good opportunity to pick up some really good, high quality growth stories that are

Read More

Immatics Announces Second Quarter 2020 Financial Results and Business Update

The MarketWatch News Department was not involved in the creation of this content.

Tuebingen, Germany and Houston, TX, Sep 03, 2020 (GLOBE NEWSWIRE via COMTEX) —
Tuebingen, Germany and Houston, TX, Sept. 03, 2020 (GLOBE NEWSWIRE) —

  • Completed merger with ARYA Life Science Acquisition Corp. and subsequent NASDAQ listing with proceeds from the transaction totaling $253 million (EUR226 million1) in July 2020.
  • At the closing of the transaction, cash and cash equivalents amounted to $322 million (EUR288 million1) enabling Immatics to fund operating expenses and capital expenditure requirements for at least 36 months.
  • Expanded ACTengine(R) clinical programs into Europe with first patient treated with genetically engineered T cell product candidate IMA202 in August 2020; regulatory approval by Paul-Ehrlich-Institute to begin phase I clinical trial with product candidate IMA203 in Germany and to open additional clinical trial sites in the EU.
  • Expanded leadership team with appointment of
Read More

Sequana Medical announces H1 2020 results and provides business update

  • POSEIDON – Implants in Canada continue; interim results expected H1 2021
  • RED DESERT – Implants continue; interim results expected Q4 2020
  • DSR (Direct Sodium Removal) – Fundamental patents allowed in U.S. and Europe
  • Continued growth in European commercial implants
  • Secured additional funding extending cash runway into H2 2021

Conference call with live webcast presentation today at 14:00 CEST / 08:00 am EST

GHENT, Belgium, Sept. 03, 2020 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces its business highlights and financial results for the six-month period ending 30 June 2020 and its outlook for the remainder of the year and into 2021.

Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: “We have continued to make good progress towards key milestones in our

Read More

iTeos Reports Second Quarter 2020 Financial Results and Provides Business Update

– July 2020 IPO provided $210.6 million in net proceeds and extends cash runway into 2023 –

– EOS-850 A2AR antagonist and EOS-448 FCgR-enabled anti-TIGIT antibody continue to progress in clinical trials –

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Sept. 01, 2020 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today reported financial results for the second quarter ended June 30, 2020 and recent business highlights.

“The completion of our successful IPO in July was a major milestone for iTeos and further supports the advancement of our highly differentiated immunotherapy pipeline, including our two lead product candidates, our adenosine A2a receptor antagonist, EOS-850, and TIGIT antagonist, EOS-448,” said Michel Detheux, PhD, President and Chief Executive Officer of iTeos. “With trials ongoing for our two lead product candidates, we anticipate that 2021

Read More

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2020

NEW YORK–(BUSINESS WIRE)–Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group” or the “Company”), a biopharmaceutical company focuses on the development of novel therapeutics to address global unmet medical needs, today provided a business update and announced financial results for the six months ended June 30, 2020.

“I am pleased with the developments that were achieved during the first half of 2020 despite the challenges presented by the COVID-19 pandemic,” said Mr. Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group. “Throughout the COVID-19 crisis, we remained focused on advancing the development of our therapeutic programs. As announced today, further positive data showing significant in vivo activities of ALS-4 (for MRSA wound healing and MRSA bacteraemia) and also in vitro and in vivo studies of SACT-1 (for neuroblastoma and other potential tumor types). Also, as an emerging company, we have been expanding our global strategic

Read More

Perimeter Medical Imaging AI Announces Update Regarding Interim Financial Statements

TORONTO, CANADA / ACCESSWIRE / August 31, 2020 / Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(FSE:4PC), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need, is providing an update on the status of the filing of its interim financial statements for its second quarter ending June 30, 2020.

On May 20, 2020, the Canadian Securities Administrators issued a notice stating that securities regulators will be providing coordinated relief consisting of a 45-day extension for certain periodic filings required to be made during the period from June 2, 2020 to August 31, 2020, as a result of the COVID-19 pandemic. Accordingly, the British Columbia Securities Commission has enacted BC Instrument 51-517 – Temporary Exemption from Certain Corporate Finance Requirements (“BCI 51-517”).

Perimeter will be relying on the temporary exemption pursuant to BCI 51-517 with respect to the requirement

Read More

Arcutis Announces Second Quarter 2020 Financial Results and Provides Business Update

  • Robust pipeline anticipated to deliver two Phase 3 and four Phase 2 data events in 2020 and 2021
  • Arcutis currently expects no impact to its previously disclosed clinical timelines due to COVID-19
  • Arcutis development programs address dermatological diseases impacting over 20 million patients in the U.S.
  • Strong financial position with $224.0 million in cash, cash equivalents and marketable securities

WESTLAKE VILLAGE, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today reported financial results for the quarter ended June 30, 2020, and provided a business update.

Frank Watanabe, Arcutis’ President and Chief Executive Officer. “Dermatologists and patients are desperate for new topical options to treat serious diseases of the skin. We are focused on elevating the standard of care for dermatological diseases and conditions through

Read More